Niclosamide Ethanolamine Salt is an upgraded water-soluble salt form of the classic anthelmintic niclosamide. Nicosamide has been used as an anthelmintic since the 1960s, but its near-insolubility in water severely limited its application in other therapeutic areas. By salting niclosamide with ethanolamine, its water solubility is increased to 180-280 mg/L, creating new possibilities for drug absorption and distribution in the body. This salt form, as a mitochondrial uncoupling agent, STAT3 signaling pathway inhibitor, and Wnt/β-catenin pathway modulator, has shown broad research value in antiviral, antitumor, and metabolic disease studies.
🧪 Optimized aniline salt formation structure improves dissolution and transmembrane permeation efficiency
The molecular skeleton of Niclosamide ethanolamine salt retains the classic planar configuration of niclosamide, a biaromatic ring salicylaniline. The chlorine atom substitution sites on the benzene ring maintain the original hydrophobic binding region, while one end is bonded to the polar side chain of ethanolamine via an ionic bond. The complete molecule possesses both a hydrophobic aromatic ring skeleton and hydrophilic amino-hydroxyl groups, perfectly balancing the lipid-water partition coefficient. It can rapidly dissociate and dissolve in aqueous solutions, phosphate buffer systems, and complete cell culture media, without exhibiting the large-scale suspension crystallization and sedimentation stratification seen with free niclosamide. In high-throughput worm viability assays and virus plaque inhibition experiments, it ensures uniform effective drug concentration in each experimental group, minimizing the bias in parallel sample data caused by poor solubility.
After penetrating the phospholipid bilayer of the cell membrane via its amphiphilic structure, the molecule undergoes ion dissociation in the weakly acidic intracellular environment, releasing the active niclosamide nucleus, which targets the mitochondrial intermembrane space. The ethanolamine accessory group is then oxidized and decomposed within hepatocytes via the amino metabolism pathway, converting into small-molecule carboxylic acid metabolites that are excreted in urine via the kidneys. The dissociated active nucleus primarily exerts its effects locally in the intestinal mucosa, parasite somatic cells, and infected host cells, with very little entry into the systemic circulation to cause long-term accumulation in the liver and kidneys. This mechanism of local accumulation and rapid metabolic clearance reduces systemic toxicological risks. In in vitro models such as long-term co-culture toxicity observation of primary hepatocytes and detection of intestinal epithelial cell barrier integrity, the mitochondrial respiratory function, proliferation activity, and baseline levels of oxidative stress in normal somatic cells can be stably maintained within physiological reference ranges, indicating a sufficiently wide safe concentration testing range.
The dissociated active component specifically binds to the mitochondrial inner membrane complex target site only in parasites and some abnormal cells. The entire Nicolasamide Ethanolamine Salt molecule cannot penetrate the nuclear pore barrier to reach deep into the genome, and will not directly embed into the DNA double-strand structure to interfere with base pairing and chromosome segregation. Even when conducting genetic safety verification at ultra-high concentration gradients far exceeding the effective dose for anthelmintic purposes, it will not induce genotoxic problems such as DNA strand breaks, gene mutations, or cell cycle disorders. In rigorous research systems such as embryonic stem cell differentiation models and in vitro safety screening of germ cells, it can avoid interference with experimental conclusions caused by non-specific damage.
The aromatic ring nucleus and mitochondrial respiratory chain proteins achieve reversible non-covalent binding through hydrophobic interactions and hydrogen bonds. When the intracellular free drug is metabolically degraded or pumped out of the cell by efflux transport proteins, the small molecule will automatically detach from the enzyme protein active site, and the mitochondrial electron transport chain can gradually restore its basic operational state. It will not cause permanent irreversible damage to mitochondria, nor will it induce compensatory overexpression of respiratory chain complex proteins, resulting in target desensitization. In the long-term drug stress passage and resistance monitoring model for parasites, the real process of pathogen metabolic recovery after the drug half-life fades can be accurately simulated, making the data analysis of resistance evolution patterns more consistent with the actual in vivo treatment status.
⚙️ Targeting mitochondria to disrupt the parasite's ATP synthesis supply
Intestinal tapeworms, flukes, and schistosomes lack a complete aerobic respiratory system and rely heavily on mitochondrial oxidative phosphorylation to synthesize adenosine triphosphate (ATP) to maintain all life activities, including muscle contraction, body surface repair, and reproduction. The active nucleus generated by the dissociation of Nicolasamide Ethanolamine Salt can precisely bind to complexes I and III of the electron transport chain in the inner mitochondrial membrane of the parasite, blocking the complete process of electron transport along the respiratory chain. The proton gradient cannot be established across the inner mitochondrial membrane, ATP synthase loses its power source and completely stops energy production, the worm's internal ATP reserves are rapidly depleted, and the muscle system loses energy support, resulting in irreversible paralysis. Unable to continue adhering to and fixing to the host's intestinal wall mucosa, the worm is ultimately expelled from the body with intestinal peristalsis. This is the core underlying mechanism by which this active pharmaceutical ingredient kills various intestinal flatworms.
The cortical cell membrane of worms contains numerous ion transport channels. Sufficient ATP is essential for maintaining the transmembrane homeostasis of potassium, calcium, and chloride ions. When mitochondrial energy synthesis is completely blocked by Niclosamide Ethanolamine Salt, the ion pumps in the worm's cell membrane lose their energy drive, leading to severe disruption of the membrane potential. A large influx of calcium ions triggers sustained muscle spasms and contractions, further accelerating worm rigidity and paralysis. Simultaneously, the integrity of the epidermal cuticle barrier is compromised, allowing digestive fluids from the host's intestines to penetrate the worm and cause internal tissue lysis and necrosis. This results in a triple-effect worm-killing effect of "energy depletion – ion imbalance – cortical damage," exhibiting stable in vitro killing activity against various types of flatworms, including pork tapeworm, beef tapeworm, broad tapeworm, and liver fluke.
Parasitic larvae and cysticerci at different developmental stages all rely on mitochondrial anaerobic respiration for energy. Nicolasamide Ethanolamine Salt can penetrate the cyst wall and act on the mitochondria of larval somatic cells within the cyst, interrupting the larval energy metabolism cycle and inhibiting larval migration, colonization, and further development within the host. In in vitro parasitic larval culture models, a series of characteristic changes can be directly observed, including decreased larval activity, morphological shrinkage, and upregulation of apoptosis signals. This approach comprehensively covers both adult worm expulsion and larval inhibition intervention stages, thus improving the research system for the mechanism of metabolic blockade throughout the entire worm life cycle.
The structure of mitochondrial respiratory chain proteins in normal mammalian somatic cells differs significantly from that in parasites. Nicolasamide Ethanolamine Salt has extremely low affinity for the human body's own aerobic respiration electron transport chain. Within the effective therapeutic concentration range, it hardly interferes with the host cell's ATP production process and does not cause adverse reactions such as muscle weakness or insufficient energy supply to organs. It selectively acts only on the metabolic system of lower invertebrate parasites. This extremely high species selectivity greatly improves the reliability of the results of in vitro host-parasite co-culture models, enabling a clear distinction between the drug's differential effects on pathogens and host cells.
🔬 Metabolic inhibitory effects extend to viruses and abnormally proliferating cells.
Many enveloped RNA viruses rely heavily on host mitochondria for energy during assembly, budding, and progeny release within host cells. Nicolasamide ethyleneamine salt reduces the ATP supply required for viral replication by moderately downregulating the efficiency of mitochondrial oxidative phosphorylation in host cells. Simultaneously, it interferes with key steps in viral envelope modification using the host vesicle transport system, hindering the complete life cycle of pathogens such as coronaviruses, rotaviruses, and influenza enveloped viruses. It is important to clarify that this effect is an indirect host metabolic regulation mechanism, not a direct target of viral proteases or polymerases. Therefore, the inhibitory effect cannot be easily escaped due to single-point viral gene mutations. This makes it suitable for long-term in vitro tracking of drug resistance evolution across multiple generations of viruses, providing a research vehicle for broad-spectrum host-guided antiviral strategies.
Rapidly proliferating tumor cells generally rely on aerobic glycolysis for energy, while exhibiting abnormally active mitochondrial respiration. Nicolasamide Ethanolamine Salt can target damaged mitochondrial complexes in tumor cells, disrupting their abnormal energy metabolism homeostasis, downregulating the expression levels of key rate-limiting enzymes in glycolysis, arresting cell cycle progression, and inducing mitochondrial apoptosis. In a three-dimensional organoid culture system of tumor spheroids, phenotypes such as shrinking spheroid proliferation volume and expanding internal hypoxic necrosis areas can be observed. This provides insights into the target mechanism of metabolically targeted antitumor lead compounds and expands the boundaries of pharmacological applications of this aniline derivative.
Niclosamide Ethanolamine Salt accumulates at high concentrations locally in the intestine. The dose absorbed into the bloodstream via the intestinal mucosa is negligible. The small amount absorbed into the bloodstream is rapidly metabolized in the liver, breaking down into inactive carboxylic acid derivatives and excreted in the urine. It does not cause long-term lipid-soluble deposition in brain tissue, bone marrow, gonads, or adipose tissue. In long-term, repeated-dose in vitro organ toxicity assessment models, the structure and function of liver and kidney cells, cardiomyocytes, and nerve cells remain normal, and the risk of chronic accumulation toxicity is negligible.
It does not have a broad-spectrum inhibitory effect on the normal symbiotic flora of the human gut. Its target is concentrated on the mitochondrial respiratory chain complex, and it does not disrupt the basic microbial metabolism of beneficial gut bacteria, such as cell wall synthesis and nucleic acid replication. In in vitro models of co-culture of intestinal epithelial cells and gut microbiota, the indirect effects of anthelmintic intervention on the gut microbiota can be independently investigated without the confounding effect of the active ingredient's antibacterial activity on experimental variables, ensuring the objectivity and purity of research results related to the intestinal barrier.
📌 Salt-modified insecticidal raw materials are adapted to a multi-dimensional scientific research system
Niclosamide Ethanolamine Salt is a core positive control standard for target research of salicylanilide antiparasitic drugs. It is primarily used to compare the inhibitory effects of free niclosamide, different salt derivatives, and other mitochondrial-targeted anthelmintics on the mitochondrial respiratory chain of tapeworms and trematodes, the duration of paralysis leading to death, and differences in cell penetration. Using Niclosamide Ethanolamine Salt, with its stable purity and excellent solubility, as a reference standard, we can systematically analyze the structure-activity relationship between benzene ring substituents and different salt-forming modifications on molecular target affinity, water solubility, worm epidermal penetration efficiency, and metabolic clearance rate. This accelerates the early structural screening and molecular optimization development of small molecule lead drugs for anti-helmintic, metabolically targeted antiviral, and antitumor purposes.
It can be used to construct various types of in vitro pathological evaluation models, simulating different pathological states such as adult intestinal worm infection, larval colonization of parasites, enveloped virus replication in host cells, and abnormal glycolytic proliferation of tumor cells through gradient concentration administration. Utilizing quantitative techniques such as worm viability microscopic counting, mitochondrial membrane potential fluorescence detection, viral copy number quantitative PCR, and tumor cell flow cytometry cycle analysis, this study comprehensively elucidates the entire action pathway of Niclosamide Ethanolamine Salt, from its dissolution across the membrane, intracellular dissociation, mitochondrial respiratory chain arrest, to pathogen energy depletion and apoptosis. It precisely delineates the minimum effective concentration thresholds for different research directions, including anthelmintic, antiviral, and antitumor effects, providing detailed and rigorous in vitro experimental data support for subsequent formulation development, excipient screening, and stability studies for suspensions and topical preparations.
In three-dimensional intestinal organoid and tumor spheroid organoid culture systems, the small molecule dissociated components can penetrate multiple layers of extracellular matrix to reach deep target cells. This highly replicates the in vivo process of drug local accumulation and efficacy beneath the human intestinal mucosal barrier and metabolic intervention in the hypoxic microenvironment of tumor cells. It overcomes the limitation of two-dimensional monolayer adherent cells in replicating the dense three-dimensional structure of tissues, significantly improving the accuracy of in vitro efficacy data in predicting in vivo intervention effects and perfecting a standardized efficacy evaluation platform for mitochondrial-targeted drugs at the organ level.
The research reagents exhibit broad compatibility, allowing for co-incubation with direct-acting antiviral small molecules, tumor chemotherapy drugs, oxidative stress inducers, and parasitic enzyme inhibitors to establish a multi-pathway synergistic intervention evaluation system. Niclosamide Ethanolamine Salt alone focuses on blocking mitochondrial energy metabolism; when combined with chemotherapy drugs, it can amplify the apoptosis effect in tumor cells. When paired with direct-acting antiviral reagents, it can achieve a dual synergistic effect of host metabolic regulation and direct viral blockade. Using this salt-modified active pharmaceutical ingredient as a core experimental tool, we deeply analyze the underlying logic of the synergistic effects of multi-target combination therapy against parasites, viruses, and tumors, expanding the complete theoretical framework for the development of new combination therapy drugs.
Conclusion
Niclosamide Ethanolamine Salt is an upgraded water-soluble salt form of the classic anthelmintic niclosamide, whose ethanolamine salt formation strategy increases the water solubility of the parent compound by approximately 30-50 times. This molecule demonstrates broad tool value in metabolic disease, antiviral, and antitumor research through a multi-target mechanism involving mitochondrial uncoupling, STAT3 inhibition, and Wnt/β-catenin regulation.
Xi'an Faithful BioTech Co., Ltd. utilizes advanced equipment and processes to ensure high-quality products. Our Niclosamide Ethanolamine Salt meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and preferred superior service make us the partner for medical institutions and researchers worldwide. If you require Niclosamide Ethanolamine Salt research or production,Please contact us Click email: allen@faithfulbio.com Or WhatsApp: +86 13137770562.
References
- Tokyo Chemical Industry. (n.d.). Niclosamide Ethanolamine Salt (Product N1261).
- MuseChem. (n.d.). Niclosamide ethanolamine salt (Product M050574).
- Sigma-Aldrich. (n.d.). Niclosamide Ethanolamine (Product 533087).
- Cayman Chemical. (n.d.). Niclosamide (ethanolamine salt) (Item No. 17118).
- WO 2017/040864 A1. Niclosamide formulations and methods of use.
- US 2023/0000803 A1. Niclosamide delayed-release composition and antiviral use thereof.
- Pharmaffiliates. (n.d.). Niclosamide Ethanolamine Salt (PA PST 019186).
- Amerigo Scientific. (n.d.). Niclosamide ethanolamine salt (Item 250782).